4.7 Review

Purinergic signaling: A gatekeeper of blood-brain barrier permeation

Journal

FRONTIERS IN PHARMACOLOGY
Volume 14, Issue -, Pages -

Publisher

FRONTIERS MEDIA SA
DOI: 10.3389/fphar.2023.1112758

Keywords

purinergic signaling; blood-brain barrier; endothelial cells; P2Y receptors; P2X receptors; P1 receptors; CD39; CD73

Ask authors/readers for more resources

This review summarizes the evidence that purinergic signaling plays a role in regulating blood-brain barrier (BBB) permeability. Various cell types, including endothelial cells, pericytes, neurons, astrocytes, microglia, and oligodendrocytes, contribute to maintaining the integrity of the BBB. Purinergic receptors such as P2Y and A receptors, as well as nucleotidases, are expressed on BBB cells and affect BBB permeability. Selective antagonists of P2Y receptors attenuate BBB damage, while agonists of A receptors protect BBB integrity. Modulating purinergic signaling could be a potential strategy for delivering therapeutic drugs to the central nervous system and restoring CNS homeostasis.
This review outlined evidence that purinergic signaling is involved in the modulation of blood-brain barrier (BBB) permeability. The functional and structural integrity of the BBB is critical for maintaining the homeostasis of the brain microenvironment. BBB integrity is maintained primarily by endothelial cells and basement membrane but also be regulated by pericytes, neurons, astrocytes, microglia and oligodendrocytes. In this review, we summarized the purinergic receptors and nucleotidases expressed on BBB cells and focused on the regulation of BBB permeability by purinergic signaling. The permeability of BBB is regulated by a series of purinergic receptors classified as P2Y(1), P2Y(4), P2Y(12), P2X4, P2X7, A(1), A(2A), A(2B), and A(3), which serve as targets for endogenous ATP, ADP, or adenosine. P2Y(1) and P2Y(4) antagonists could attenuate BBB damage. In contrast, P2Y(12)-mediated chemotaxis of microglial cell processes is necessary for rapid closure of the BBB after BBB breakdown. Antagonists of P2X4 and P2X7 inhibit the activation of these receptors, reduce the release of interleukin-1 beta (IL-1 beta), and promote the function of BBB closure. In addition, the CD39/CD73 nucleotidase axis participates in extracellular adenosine metabolism and promotes BBB permeability through A(1) and A(2A) on BBB cells. Furthermore, A(2B) and A(3) receptor agonists protect BBB integrity. Thus, the regulation of the BBB by purinergic signaling is complex and affects the opening and closing of the BBB through different pathways. Appropriate selective agonists/antagonists of purinergic receptors and corresponding enzyme inhibitors could modulate the permeability of the BBB, effectively delivering therapeutic drugs/cells to the central nervous system (CNS) or limiting the entry of inflammatory immune cells into the brain and re-establishing CNS homeostasis.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available